Vinpocetine
Star3
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Vinpocetine is a synthetic derivative of a vinca alkaloid used to treat neurological symptoms of cerebrovascular disease.
- Generic Name
- Vinpocetine
- DrugBank Accession Number
- DB12131
- Background
Vinpocetine has been investigated for the treatment of Epilepsy.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 350.462
Monoisotopic: 350.199428085 - Chemical Formula
- C22H26N2O2
- Synonyms
- CERACTIN
- ETHYL APOVINCAMIN-22-OATE
- Vinpocetina
- Vinpocetine
- External IDs
- AY-27255
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Symptomatic treatment of Cerebrovascular stenosis •••••••••••• Symptomatic treatment of Neurological disorders •••••••••••• •••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of CNS depression can be increased when Vinpocetine is combined with 1,2-Benzodiazepine. Abametapir The serum concentration of Vinpocetine can be increased when it is combined with Abametapir. Acarbose The risk or severity of hypoglycemia can be increased when Vinpocetine is combined with Acarbose. Acebutolol Acebutolol may increase the arrhythmogenic activities of Vinpocetine. Aceclofenac The risk or severity of hyperkalemia can be increased when Aceclofenac is combined with Vinpocetine. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- ATC Codes
- N06BX18 — Vinpocetine
- Drug Categories
- Agents causing hyperkalemia
- Alkaloids
- Antiarrhythmic agents
- Anticonvulsants
- Bradycardia-Causing Agents
- Calcium Channel Blockers
- Cardiovascular Agents
- Central Nervous System Agents
- Central Nervous System Depressants
- Compounds used in a research, industrial, or household setting
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 Substrates
- Enzyme Inhibitors
- Heterocyclic Compounds, Fused-Ring
- Indole Alkaloids
- Indoles
- Indolizidines
- Indolizines
- Nervous System
- Neuroprotective Agents
- Nootropic Agents
- Phosphodiesterase Inhibitors
- Protective Agents
- Psychoanaleptics
- Psychostimulants, Agents Used for ADHD and Nootropics
- Secologanin Tryptamine Alkaloids
- Vasodilating Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as eburnan-type alkaloids. These are alkaloids with a structure based on the eburnan skeleton, that arises from rearrangement of the aspidospermidine ring system, involving migration of C-21 from C-7 to C-2, fission of the 2,16-bond, and attachment of C-16 to N-1.
- Kingdom
- Organic compounds
- Super Class
- Alkaloids and derivatives
- Class
- Eburnan-type alkaloids
- Sub Class
- Not Available
- Direct Parent
- Eburnan-type alkaloids
- Alternative Parents
- Indolonaphthyridine alkaloids / Beta carbolines / 3-alkylindoles / Alpha amino acids and derivatives / Naphthyridines / Aralkylamines / Piperidines / Benzenoids / Pyrroles / Heteroaromatic compounds show 8 more
- Substituents
- 3-alkylindole / Alpha,beta-unsaturated carboxylic ester / Alpha-amino acid or derivatives / Amine / Amino acid or derivatives / Aralkylamine / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Beta-carboline show 25 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 543512OBTC
- CAS number
- 42971-09-5
- InChI Key
- DDNCQMVWWZOMLN-IRLDBZIGSA-N
- InChI
- InChI=1S/C22H26N2O2/c1-3-22-11-7-12-23-13-10-16-15-8-5-6-9-17(15)24(19(16)20(22)23)18(14-22)21(25)26-4-2/h5-6,8-9,14,20H,3-4,7,10-13H2,1-2H3/t20-,22+/m1/s1
- IUPAC Name
- ethyl (15S,19S)-15-ethyl-1,11-diazapentacyclo[9.6.2.0²,⁷.0⁸,¹⁸.0¹⁵,¹⁹]nonadeca-2,4,6,8(18),16-pentaene-17-carboxylate
- SMILES
- [H][C@]12N3CCC[C@@]1(CC)C=C(N1C4=CC=CC=C4C(CC3)=C21)C(=O)OCC
References
- General References
- FDA Thailand Product Information: Cavinton (vinpocetine) for oral use [Link]
- External Links
- PubChem Compound
- 443955
- PubChem Substance
- 347828430
- ChemSpider
- 392007
- BindingDB
- 50059033
- 24506
- ChEBI
- 32297
- ChEMBL
- CHEMBL71752
- ZINC
- ZINC000019796031
- PDBe Ligand
- T7F
- Wikipedia
- Vinpocetine
- PDB Entries
- 8i5x
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 2, 3 Completed Treatment Immunoregulation / Inflammation / Stroke / Vinpocetine 1 1, 2 Suspended Treatment Epilepsy 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Parenteral 20.000 mg Tablet Oral 10 mg Tablet Oral 5 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0254 mg/mL ALOGPS logP 4.35 ALOGPS logP 4.07 Chemaxon logS -4.1 ALOGPS pKa (Strongest Basic) 6.94 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 34.47 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 104.24 m3·mol-1 Chemaxon Polarizability 40.31 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 192.5003072 predictedDarkChem Lite v0.1.0 [M-H]- 186.19145 predictedDeepCCS 1.0 (2019) [M+H]+ 193.4916072 predictedDarkChem Lite v0.1.0 [M+H]+ 188.54944 predictedDeepCCS 1.0 (2019) [M+Na]+ 193.0215072 predictedDarkChem Lite v0.1.0 [M+Na]+ 194.6426 predictedDeepCCS 1.0 (2019)
Enzymes
1. DetailsCytochrome P450 3A4
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Uesawa Y, Takeuchi T, Mohri K: Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17. [Article]
Drug created at October 20, 2016 21:24 / Updated at May 21, 2021 10:22